Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone and Degarelix in Recurrent Prostate Cancer
NCT01751451Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2012
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Abiraterone Acetate Tablets (I) in prostate cancer (PCa) (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Progression-free Survival at 18 months and Soft Tissue Complete Response at 1 year. Started Dec 2012; status: completed.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01751451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01751451.